Similar to its therapeutic effects in experimental studies112,113, the C-C motif chemokine receptor 2/5 (CCR2/5) antagonist cenicriviroc (CVC) improved hepatic fibrosis and systemic inflammation in NASH patients114. The gene discussed is CCR2; the disease is metabolic dysfunction-associated steatohepatitis.